Cns Pharmaceuticals Inc(CNSP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 4:00 PM ET (Korea 11/3 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -23.59 | Insider Own | 1.44% | Shs Outstand | 1.5M | Perf Week | -5.08% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | 76.13% | Shs Float | 1.4M | Perf Month | -17.56% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 19.19% | Short Float | 0.09% | Perf Quarter | -18.1% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | 5.12% | Short Ratio | 0.14 | Perf Half Y | -44.01% |
| Sales | 0.00B | P/B | 0.35 | EPS next 5Y | - | ROA | -91.64% | Short Interest | 0.00M | Perf YTD | -16.38% |
| Book/sh | 12.45 | P/C | 0.32 | EPS past 3/5Y | 95.26% 85.25% | ROE | -106.62% | 52W High | -58.35% ($10.54) | Perf Year | -42.99% |
| Cash/sh | 13.67 | P/FCF | - | Sales past 3/5Y | - | ROIC | -91.75% | 52W Low | 131.05% ($1.90) | Perf 3Y | -99.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 88.43% | Gross Margin | - | Volatility(W/M) | 22.21% 10.79% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.55 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.85 | EPS Q/Q | 94.1% | Profit Margin | - | RSI (14) | 39.94 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.85 | Sales Q/Q | - | SMA20 | -12.67% ($5.03) | Beta | 1.02 | Target Price | $10 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -17.72% ($5.34) | Rel Volume | 1.61 | Prev Close | $5 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -58.33% - | SMA200 | -4.4% ($4.59) | Avg Volume(3M) | 0.01M | Price | $4.39 |
| IPO | 2019/11/8 | Option/Short | No/Yes | Trades | 177 | Volume | 15,108 | Change | -12.2% |
🧠 Brain cancer drug developer. TPI 287 for glioblastoma treatment. 52% response rate in clinical results. Strategic pivot in 2026. $2.1M in cash.
Over the past 1 year, roughly in the middle
58% below its 1-year high.
Traded more than usual. That is 161% of its average volume.
CNSP has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #529 of 597 in the industry
Based on market cap of $6M.
EVGN#527 Evogene Ltd $7M PER - 
ENVB#528 Enveric Biosciences Inc $6M PER - CNSP#529 Cns Pharmaceuticals Inc $6M PER - 
AIM#530 AIM ImmunoTech Inc $6M PER - 
TCRT#531 Alaunos Therapeutics Inc $6M PER - 
FAQ
What kind of company is CNSP?
CNSP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CNSP?
The market cap of CNSP is approximately $6M, ranking 5,552 within its sector.
What is the 52-week high and low for CNSP?
CNSP has recorded a 52-week high of $10.54 and a low of $1.90.
